Epidemiological Associations of Various Substances and Multiple Cannabinoids with Autism in USA

Albert Stuart Reece1,2* and Gary Kenneth Hulse1,2

1Division of Psychiatry, University of Western Australia, Crawley, Western Australia, Australia; 2School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia

ABSTRACT

Introduction: Autistic Spectrum Disorder (ASD) is increasing in across USA. Paediatricians and physicians in both Colorado and Australia continue to see high caseloads however this prevalence uptick remains largely unexplained. Since drug use is an obvious potential source of developmental brain damage the present study was undertaken to study drug-ASD associations at state level.

Methods: Existing datasets from the US Department of Education Individuals with Disabilities Act, the Substance Abuse and Mental Health Services Administration National Survey of Drug Use and Health, and the Drug Enforcement Agency cannabinoid concentration in seizures were re-analyzed.

Results: ASD rates are high and rising fastest in Colorado, Maine, Massachusetts, Oregon, Rhode Island and New Jersey but falling in Oklahoma and Iowa. When the nine highest cannabis use states are grouped together ASD is rising significantly faster there than elsewhere (time:status interaction in quadratic mixed effects model p<0.0001). On univariate regression ASD rate was significantly positively associated with alcohol and cannabis exposure and with the cannabinoids Δ9-tetrahydrocannabinol, cannabidiol, cannabichromene, cannabigerol and tetrahydrocannabivarin. These effects remained after multivariate adjustment for Δ9-tetrahydrocannabinol and cannabidiol (from p<0.0001). Cannabidiol correlated with ASD rate when a three year lag was introduced (R=0.7483, p=0.0032).

Conclusion: These data show that increased cannabinoid exposure explains on bivariate and multivariate regression much of the recent rise in ASD across USA, and in the context of other reports, also at some local cluster levels. Together with numerous mechanistic reports these data argue for causality and indicate a large case-control study. ASD-like neurobehavioural toxicological syndromes likely represent the commonest form of cannabis-related teratology following peri-gestational exposure.

Keywords: Cannabis; Opioids; Cannabidiol; Cannabinol; Tetrahydrocannabinol; Autism spectrum disorder

Abbreviations: ASD: Autism Spectrum Disorder; CB1R: Cannabinoid type 1 receptor; DEA: Drug Enforcement Agency; IDEA: US Department of Education Individuals with Disabilities Act; NSDUH: National Survey of Drug Use and Health; Robo: Roundabout, a guidance molecule receptor for axonal growth cones and arterial endothelial tips; SAMHSA: Substance Abuse and Mental Health Services Administration; Slit: Slits 1-3, arterial and axonal guidance molecule and ligand for Robo; +: An additive operator for regression calculations; ~: Tilde, a middle sign separating the two sides of a regression calculation; *: Asterisk, an operator used in regression calculations to include additive and interactive relationships.

INTRODUCTION

Autistic spectrum disorder (ASD) is one of the commonest development abnormalities of children affecting a mean of 1.68% of 8 year old boys across USA and up to 4.5% of 8 year old boys in New Jersey [1]. Surveys show substantial rates of rise in ASD incidence of 20% over two years in New Jersey and 30% in Colorado. Indeed a recent bill was placed before the Colorado
House of Representatives to have autism declared a state of emergency in various Colorado counties [2].

Whilst many previous epidemiological studies have been conducted the cause/s remain largely elusive. Higher socioeconomic status, having a previous autistic child, advanced parental age, gestational inflammation, twin associations, diabetes, bleeding and drugs [3-5] including cannabinoids [6,7] have been previously implicated.

Three of three longitudinal studies of cannabis use have confirmed impairments of executive and cortical functioning and ADHD- and autistic- like cognitive deficits following Prenatal Cannabis Exposure (PCE) [8-11]. This compelling prospective evidence would appear to place an epidemiological and mechanistic link between ASD and cannabinoid consumption on a firm scientific foundation.

A large Hawaiian study of 300,000 deliveries found 21 major birth defects were elevated after PCE [12]. Since ASD is commoner than the commonest of these defects, and since neurobehavioural toxicoology is likely to be a power (squared) or pseudo-exponential function of exposure to multiple cannabinoids, in the context of rising cannabinoid use, using Δ9tetrahydrocannabinol concentrations, and cannabinoids now entering the US food chain, it would appear that ASD-like neurobehavioural toxicoology will increasingly become the leading manifestation of increased gestational cannabinoid exposure. In 2017 161,000 women in USA used cannabis whilst pregnant; and for 69,000 use was near-daily [13].

Many reports of cannabinoid toxicoology and genotoxicity suggest an asymptotic (steeply rising) pseudo-exponential (mimicking an exponential rise) dose-response relationship [14-18]. The implications of this on neurobehavioural neurotoxicology and general toxicoology may prove to be most profound as the population moves into a higher cannabis use paradigm.

It is important to note that cannabinoids have been shown previously to be involved in numerous pathways impacting brain development so that many molecular, cellular and neurodevelopmental links between cannabinoid exposure and brain pathology have been described. Potential mechanisms by which cannabinoids could impact brain development and function relevant to ASD expression are manifold and have been reviewed elsewhere [8,19-23] and this is briefly summarized here. 

Cannabinoids negatively affect neurogenesis a process critically important in the developing brain for the long distance migration of human neocortical neurons and the formation of the large and exuberant human cortex [24,25]. By interfering with the formation of actin and tubulin which forms the microtubules of the mitotic spindle THC interferes with cell division [21]. THC interferes with notch signalling [26,27] which is a key body morphogen and especially important for brain and heart morphogenesis [28-31]. The endocannabinoid system is a key regulator of synaptogenesis [32,33]. The neurexin-neuroligin scaffolding pair is a key transsynaptic membrane complex governing synapse development and stabilization which is impeded by exogenous phytocannabinoids [34]. Cannabinoids affect immune and microglial function and thus synaptic pruning and ability to focus, concentrate and learn from experience [35]. Cannabinoids interfere with stathmin which is a key molecular pathfinder for growth cone steering and guidance [36] and has also been shown to be involved with synaptogenesis, neurogenesis and NMDA dependent memory [37].

The ratio of the guidance molecules slit to robo has been shown to be a key regulator of human and mammalian cortical development and diverts foetal subventricular neurogenesis from a small-capacity direct pathway to a slower but more prolific indirect pathway and is immediately responsible for the large human neocortex [25]. This ratio is adversely affected by cannabinoids [24]. Slit/Robo also guide axons [24]. Mitochondria carry a full complement of endocannabinoid signalling machinery [38,39] and not only generate the energy for DNA protection and maintenance but also signal directly to the nuclear genome by several metabolic pathways and shuttles [40] and are impeded by cannabinoids [16-18, 41-43] in a manner which directly interferes with major neuronal functions including signalling and memory [38,39]. Acting via type 1 endocannabinoid receptors (CB1R’s) cannabinoids are proinflammatory [44,45] which negatively impacts neurogenesis [19,38,46-48]. Cannabinoids can have deleterious effects on macro and micro-vasculature and the stem cell niches to which they contribute [49-52]. Negative effects have been documented on both sperm [53-56] and ova [57]. Foetal alcohol syndrome is known to act epigenetically in part via CB1R’s [58]. Exogenous cannabinoids are also known to suppress the cortical oscillations which are increasingly being understood to be fundamental to many cortical functions [59].

Finally cannabinoids including small doses of Δ9-tetrahydrocannabinol, cannabinol, cannabichromene and cannabidivarain are known to have substantial epigenetic effects [60-63] a finding which achieves particular significance in the light of the large literature on the epigenetic aetiopathogenesis of ASD [64,65].

Since the USA regularly surveys drug use in a nationally representative sample [13] and is undergoing a period of social change in relation to the use of cannabis and other drugs we investigated the extent to which extant epidemiological evidence of drug and cannabinoid use were associated with ASD incidence at the ecological level. Since the link between cannabinoid use and ASD-like syndromes has already been established by prior work, we limited ourselves to a consideration of the extent to which this previously demonstrated link might be reflected in currently available national datasets. Whilst it is not possible to demonstrate causality in an ecological-associational level study in the interpretation of our findings we gave careful consideration to the relationship between our results and the criteria of causality as outlined by Bradford Hill in 1965 [66].

METHODS

Data sources

Data on the US National Database from the US Department of Education Individuals with Disabilities Act (IDEA) was used [67]. Data on state level use of various addictive drugs were sourced from the Substance Abuse and Mental Health Administration (SAMHSA) National Survey of Drug Use and Health (NSDUH) including shapefiles and SAS database files [13]. Data on cannabinoid concentration of US Drug Enforcement Agency (DEA) Seizures were from published sources [68,69]. State based levels of individual cannabinoids were derived by multiplying the monthly cannabis use by the Federal concentration of each cannabinoid separately.
Figure 1: Maps of cannabis use, autism spectrum disorder and cannabis and autism together. A: Monthly cannabis use by State. B: Annual autism spectrum disorder by US State, 2011. Bivariate color plane choropleth map of cannabis and autism co-variance.
Statistics

Data were analyzed in “R” from Central R Archive Network version 3.5.2 and R Studio 1.1.463 2018. Parameters were log transformed to optimize normality assumptions where appropriate. Models were compared using analysis of variance procedures. Time was not transformed. Full regression models were reduced following the classical procedure of elimination of the least significant term. Maps and graphs were plotted in ggplot2. Bivariate maps were drawn using colorplaner 0.1.4. Time series analysis was performed with the stats package. Two-tailed t-tests of statistical significance were used throughout. P<0.05 was considered significant.

Ethics

These studies were approved by the Human Research Ethics Committees of Southcity 7-Day Family Medical Centre in Brisbane, Australia and the University of Western Australia in Crawley, Perth, Western Australia.

RESULTS

Data from the IDEA database were combined with SAMHSA NSDUH and DEA published data on levels of cannabinoid concentration identified in Federal seizures of drugs to analyze the relationship between autism rates and drug use at US state level [13,67-69].

Figure 1: A shows a map of US states by rates of last month cannabis consumption, Figure 1B shows a US state-based map of ASD rates, and Figure 1C shows a bivariate colorplane map of both parameters together on the same plot. Purple shading in Figure 1C indicates that both last month cannabis use and autism are high in California.
Supplementary Figures 1A and B shows the rate of ASD in 25 and 26 states respectively.

Figure 2 shows the published concentration of seven different cannabinoids over time in Federal seizures at the national level \[68,69\].

Figures 3 and 4 illustrate the rates of ASD in 25 and 26 states respectively. The data have been split into two sets to assist with over plotting. A combined plot appears as Supplementary Figure 2. Figure 4 shows high levels of ASD in Minnesota, Colorado, Maine and Massachusetts and low and decreasing levels in Iowa. Figure 5 shows high ASD levels in Oregon, Rhode Island and New Jersey but low and flattening out levels in Oklahoma.

The relationship of the ASD rate to time appears to concave upwards. Plotting of the square root of the ASD rate against time linearizes this relationship as shown in Supplementary Figure 3. This comparison can be formalized by conducting an analysis of variance (ANOVA) study of models of ASD rate linear and quadratic in time. The AIC of the linear model is \(1726.158\) and that of the quadratic model is \(1557.113\) \((F=185.63, \text{df}=1, p<2.0\times10^{-16})\). This result confirms that the model quadratic in time provides superior fit to the data.

When the ASD rate is regressed against quadratic time and state using Iowa as the baseline comparator 128 terms are significant (Supplementary Table 1).

Figure 5 presents a geofacetted plot of the rate of autism against cannabis use in each state. This graph plot sets out a scatterplot of the ASD rate against cannabis use for each state with each state in the approximate position it occupies in the USA and forms a very clear way to compare the scatterplots and their regression lines.
### Linear Models

| Parameter                                      | Parameters | Model          |
|-----------------------------------------------|------------|----------------|
|                                              | Est.       | Std. Error     | Pr(>|t|) | Adj. R Squ | F    | df | p       |
| Autism ~ Time * factor (Cannabis_Exposure)    |            |                |         |            |      |     |         |
| Time                                          | 0.196      | 0.0073         | 26.69   | <2e-16     | 0.781 | 1210| <2.0E-16 |
| Cannabis_High                                 | -36        | 16.1           | -2.239  | 0.025      |      |     |         |
| Time: Cannabis_High                           | 0.0179     | 0.008          | 2.237   | 0.026      |      |     |         |
| Autism ~ (Time)2 * factor (Cannabis_Exposure) |            |                |         |            |      |     |         |
| Time                                          | 40.224     | 1.3512         | 29.77   | <2e-16     | 0.815 | 1120| 41,018 | <2.0E-16 |
| (Time)2                                        | -9.114     | 1.3561         | -6.72   | 3.00E-11   |      |     |         |
| Time: Cannabis_High                           | 4.1692     | 1.4778         | 2.82    | 0.0049     |      |     |         |

### Mixed Effects Models

| Parameter                                      | Parameters | Model          |
|-----------------------------------------------|------------|----------------|
|                                              | Value      | Std. Error     | dF     | t-value  | p    | AIC  | BIC  | Log Lik |
| 2005-2013                                      |            |                |        |          |     |      |      |         |
| Autism ~ Time * factor (Cannabis_Exposure), State as Random |            |                |        |          |     |      |      |         |
| Time                                          | 0.1782     | 0              | 970    | 34       | 0    | 1386 | 1415 | -687    |
| Cannabis_High                                 | -38.39     | 13             | 49     | -3       | 0.004|      |      |         |
| Time:Cannabis_High                            | 0.0192     | 0              | 970    | 3        | 0.002|      |      |         |
| Autism ~ (Time)2 * factor (Cannabis_Exposure), State as Random |            |                |        |          |     |      |      |         |
| Time                                          | 33.305     | 0.4064         | 968    | 81.9506  | 0    | 1031 | 1065 | -508    |
| (Time)2                                        | -6.995     | 0.4065         | 968    | -17.21   | 0    |      |      |         |
| Time:Cannabis_High                            | 4.1333     | 0.9955         | 968    | 4.1521   | 0    |      |      |         |
| (Time)2:Cannabis_High                         | -2.125     | 0.9978         | 968    | -2.1295  | 0.034|      |      |         |

### Table 2: Univariate Relationship of ASD Rate to Substance and Cannabinoid Exposure.

| Parameter                                      | Parameters | Model          |
|-----------------------------------------------|------------|----------------|
|                                              | Est.       | Std. Error     | t value | Pr(>|t|) | Adj. R Squ | F    | df | p       |
| Autism Rate ~ Substance Use                   |            |                |         |         |            |      |     |         |
| Alcohol Monthly                               | 2.8724     | 0.3081         | 9.322   | <2.0E-16 | 0.116    | 86.9 | 1,656| <2.0E-16 |
| Binge Alcohol Monthly                         | 4.0727     | 0.7451         | 5.466   | 6.60E-08 | 0.042    | 29.9 | 1,656| 6.55E-08 |
| Cigarettes Monthly                            | -6.799     | 0.7468         | -9.104  | <2.0E-16 | 0.111    | 82.9 | 1,656| <2.0E-16 |
| Cocaine Annual                                | -0.239     | 0.0861         | -2.733  | 0.0057   | 0.01     | 7.69  | 1,656| 0.0057   |
| Pain Relievers Annual                         | 0.0049     | 0.2026         | 0.024   | 0.9806   | -0.006   | 0    | 1,174| 0.9806   |
| Cannabis Monthly                              | 0.9099     | 0.0839         | 10.84   | <2.0E-16 | 0.151    | 118  | 1,656| <2.0E-16 |
| Cannabis Annual                               | 0.778      | 0.1093         | 7.115   | 3.47E-12 | 0.082    | 50.6 | 1,544| 3.47E-12 |
| Autism Rate ~ Cannabinoid Use                 |            |                |         |         |            |      |     |         |
| THC Monthly                                    | 0.9768     | 0.0418         | 23.36   | <2.0E-16 | 0.453    | 546  | 1,656| <2.0E-16 |
| Cannabidiol Monthly                            | -0.122     | 0.0749         | -1.623  | 0.105    | 0.003    | 2.63  | 1,656| 0.1051   |
| Cannabinol Monthly                             | 0.6155     | 0.0713         | 8.637   | <2.0E-16 | 0.101    | 74.6  | 1,656| <2.0E-16 |
| Cannabichromene Monthly                       | 1.0752     | 0.0598         | 18      | <2.0E-16 | 0.33     | 324  | 1,656| <2.0E-16 |
| Cannabigerol Monthly                           | 0.8907     | 0.0475         | 18.75   | <2.0E-16 | 0.348    | 352  | 1,656| <2.0E-16 |
| Tetrahydrocannabivarin Monthly                | 0.8959     | 0.0697         | 12.85   | <2.0E-16 | 0.2      | 165  | 1,656| <2.0E-16 |
for each state. One note that in each case the data falls closely on
the least squares regression lines with different, albeit generally
increasing trends with cannabis use, in each state.

States may be divided into average and high cannabis use rates
based on the most recent results of the SAMHSA NSDUH. In this
survey the states of Colorado, Alaska, Washington state, Oregon,
Montana, Massachusetts Washington DC, Rhode Island and
Vermont were the nine highest ranking states. When these states
were classed as high use the graph shown in Figure 6 is obtained.
Table 1 shows the outcome of linear regression procedures on this
data for both linear models and for mixed effects models with the
state as a random effect, for models linear and quadratic in time in
both cases. As shown in Table 1, many terms are highly significant
and the time: cannabis_use_status interaction is significant in all
models from p<0.0001. Models quadratic in time were superior to
the linear-only models for both linear and mixed effects models
(linear models: F=189, dF=1, p<2.0x10 -16; random effects models
log ratio=333, p<0.0001).

The mean ASD rates in high v low states was 100.11+14.21 v
93.64+5.39 (p=0.6791).

Figure 7 plots the ASD rate against the use by state of the various
addictive agents. Positive slopes of lines are obtained for alcohol
and cannabis. These relationships are quantified by regression
studies in the upper half of Table 2. There one notices highly
significant and positive β-estimates for cannabis by both monthly
and annual measures of use.

For this reason cannabinoids were broken down by the major ones
for which data is available at the time of writing. The data are
presented graphically in Figure 8. One notes a positive slope for
eight of the cannabinoids, but an apparently slightly negative slope
for cannabidiol.

Figure 4: Autism spectrum disorder rates in States Missouri -Wyoming. (Source: Data from IDEA dataset).
Figure 5: Geo-faceted plot of autism rate by cannabis use by US state with states set out in approximate geographical location across USA.
These effects are quantitated in the lower half of Table 2 which confirms strongly positive relationships for the five cannabinoids Δ9-tetrahydrocannabinol (THC), cannabinol, cannabichromene, cannabigerol and tetrahydrocannabivarin. The analysis in Table 2 shows that the slope of the regression line for cannabidiol is not significantly different from zero (t=-1.623, p=0.1050).

Having demonstrated in single variable analyses an apparent relationship between the use of various substances and the ASD rate, a natural consideration related to the relative importance of the various substances on linear regression. Table 3 explores this question. When all cannabinoids are regressed against ASD rate in a simple linear additive model only cannabidiol is significant (β-estimate=10.2, p<0.0001). When a model employing interactive terms in cannabinoid use is used the results are as shown in the second part of Table 3 which find that both THC (β-estimate=1.3, p=0.0001) and cannabidiol (β-estimate=4680.0, p=0.0007) are significant.

When all the different substances were compared in a simple additive model the results obtained in the middle of Table 3 are derived.

When all the substances (excluding cannabis) and all the individual cannabinoids are regressed against the ASD Rate the results shown in the lower part of Table 3 are obtained. It is interesting to note that cannabidiol survives model reduction in nine terms from

![Figure 6: Autism spectrum disorder rates over time by High vs. Average cannabis use states.](image-url)
| Parameter | Parameters | Model |
|-----------|------------|-------|
|           | Est. | Std. Error | t value | Pr(>|t|) | Adj. R Squ | F | df | p   |
| **1991-2011** |     |     |     |     |     |     |     |
| *Linear Additive Model w All Cannabinoids* |     |     |     |     |     |     |     |
| Time      | 0.132 | 0.0045 | 29.54 | <2.0E-16 | 0.571 | 438 | 2,655 | <2.0E-16 |
| CBD       | 10.2  | 1.91   | 5.32  | 0.0000   |     |     |     |     |
| *Interactive Model w All Cannabinoids* |     |     |     |     |     |     |     |
| Time:THC:CBD | -0.022 | 0.0051 | -4.19 | 0.0000 | 0.582 | 184 | 5,652 | <2.0E-16 |
| THC       | 1.33  | 0.33   | 4.03  | 0.0001   |     |     |     |     |
| Time:CBD  | 2.35  | 0.687  | 3.43  | 0.0007   |     |     |     |     |
| CBD       | -4680 | 1370   | -3.41 | 0.0007   |     |     |     |     |
| **1995-2011** |     |     |     |     |     |     |     |
| *All Drugs Additive Model* |     |     |     |     |     |     |     |
| Alcohol   | 3.4918 | 0.7474 | 4.67  | 0.0000 | 0.432 | 23.2 | 6,169 | <2.0E-16 |
| Binge_Alcohol | -8.268 | 1.8225 | -4.54 | 0.0000   |     |     |     |     |
| Tobacco   | -12.59 | 3.7767 | -3.33 | 0.0011   |     |     |     |     |
| Cigarettes| 13.728 | 4.7634 | 2.88  | 0.0045   |     |     |     |     |
| Cocaine   | 16.323 | 6.6386 | 2.46  | 0.0149   |     |     |     |     |
| *All Drugs Interactive Model* |     |     |     |     |     |     |     |
| Cigarettes:Alcohol | -256 | 45 | -5.73 | 0.0000 | 0.497 | 10.6 | 18,157 | <2.0E-16 |
| Cigarettes:CBD:Alcohol | 9280 | 2020 | 4.59 | 0.0000   |     |     |     |     |
| CBD:Alcohol | -1450 | 339 | -4.29 | 0.0000   |     |     |     |     |
| Cigarettes:CBD | -2E+05 | 41900 | -3.82 | 0.0002   |     |     |     |     |
| Time:Cigarettes:CBD | 78 | 21 | 3.75 | 0.0003   |     |     |     |     |
| CBD       | 711   | 192   | 3.71  | 0.0003   |     |     |     |     |
| Cigarettes:THC:CBD | 583000 | 165000 | 3.54 | 0.0005   |     |     |     |     |
| Time:Cigarettes:THC:CBD | -290 | 82 | -3.55 | 0.0005   |     |     |     |     |
| Time:Cigarettes:THC | 0.0208 | 0.006 | 3.45 | 0.0007   |     |     |     |     |
| Time:Cigarettes:THC:CBD:Alcohol | 449 | 131 | 3.44 | 0.0007   |     |     |     |     |
| Cigarettes:THC:CBD:Alcohol | -9E+05 | 263000 | -3.44 | 0.0008   |     |     |     |     |
| Cigarettes | 6520 | 2090 | 3.11 | 0.0022   |     |     |     |     |
| Time      | 0.894 | 0.29  | 3.08  | 0.0024   |     |     |     |     |
| Time:Cigarettes | -3.2 | 1.04 | -3.08 | 0.0024   |     |     |     |     |
| Time:THC  | -0.003 | 0.0013 | -2.16 | 0.0325   |     |     |     |     |
| Alcohol   | 1750  | 817   | 2.14  | 0.0338   |     |     |     |     |
| Time:Alcohol | -0.848 | 0.406 | -2.09 | 0.0382   |     |     |     |     |
| Binge_Alcohol | -4.01 | 1.95 | -2.05 | 0.0417   |     |     |     |     |

THC: Δ9-tetrahydrocannabinol; CBD: Cannabidiol; CBN: Cannabinol
Figure 7: Autism spectrum disorder rates by substance exposure levels.
Figure 8: Autism spectrum disorder rates by cannabinoid exposure levels.
Figure 9: Autism spectrum disorder by cannabidiol exposure rate by year. (Source: US National data)
Figure 10: Lag analysis of slope of autism spectrum disorder rate–cannabidiol concentration association by time and group.
p<0.00001, and terms including Δ9-tetrahydrocannabinol occur six times (from p=0.0005).

When this exercise is repeated in a random effects mixed interactive model with state as a random effect, similar results are obtained (Table 4). Here Δ9-tetrahydrocannabinol is seen in four terms, cannabidiol in eight terms and cannabinol in one term.

The above analysis seems to present mixed evidence relating to the effect of cannabidiol on the ASD rate. For this reason its relationship was explored further.

One note from Figure 2 that cannabidiol has a biphasic relationship with time having risen and then fallen since it is understood to be regulated in a manner opposite to Δ9-tetrahydrocannabinol in the Cannabis sativa plant. It is conceivable that this biphasic rise and fall is creating some confusion in the analysis since cannabidiol alone of all the cannabinoids assessed, does not display a unidirectional trend.

For this reason Figure 9 charts the ASD-cannabidiol data by individual year. Visual inspection suggests that there appears to be a rise in the slope of the least squares regression line till about 2007 and a subsidence thereafter. Careful inspection of Figure 2C shows that the cannabidiol concentration curve of Federal seizures apparently maximized in about 2002 which suggests a possible time lagged effect (Supplementary Table 2).

Figure 10A shows the slopes of the regression lines of Figure 9 against time and compares it to the curve for the cannabidiol concentration. An apparent time lag effect is seen.

Supplementary Figure 4 shows autocorrelation and partial autocorrelation plots of this data. Supplementary Figure 5 presents a cross-correlation graph of the cannabidiol and ASD-cannabidiol slope data which indicates that the correlation maximizes around a lag of 3-4 years.

Figure 10B re-draws the plot of Figure 10A with a three-year lag added to the cannabidiol concentration curve. This has the effect of raising the cannabidiol–ASD-cannabidiol slope correlation from R=0.0165 (95%C.I. -0.5393–0.5624), t=0.0549, df=11, p=0.9572 up to R=0.7483 (95%C.I. 0.3357-0.9199), t=3.7414, df=11, p=0.0033.

Hence this more detailed analysis suggests that notwithstanding the declining cannabidiol content of US cannabis seizures, cannabidiol is indeed associated with the ASD rate, albeit after a lag period of 3-4 years or thereabouts. The salience of cannabidiol in the several multiple regression tabulations (Tables 3 and 4) described above is also clear.

**DISCUSSION**

Despite calls by at least two US Surgeons General [70,71] on the risks associated with drug use during pregnancy, and strong warnings by the American College of Obstetricians and Gynecologists [72] the issue of drug use in pregnancy and possible increases in neonatal morbidity has not been fully investigated. In the light of recent emerging data identifying drug-related causal pathways for neonatal morbidity, this study investigated the relationship between epidemiological data on US state-based drug use and the incidence of ASD, particularly to investigate the apparently mystifying rise in many parts of the USA and elsewhere.

This study confirmed that ASD is rising in all states except Iowa and Oklahoma. The overall trend shows a quadratic time-dependent increase. When the high cannabis use states of Colorado, Alaska, Washington state, Oregon, Montana, Massachusetts Washington DC, Rhode Island and Vermont are grouped together the ASD rate is rising faster than in the remainder of the country (time:status interaction p=0.0049 in a quadratic-time model). In the period 1995-2011 ASD rose with alcohol and cannabis use but not with opioid pain relievers, tobacco and cocaine. Upon multivariate testing terms including alcohol, cigarettes, Δ9-tetrahydrocannabinol, cannabidiol and cannabinol remained significant in final models.

The effect of cannabidiol was complex due to its inverted U-shaped time trend but was confirmed to be associated with ASD rates on lagged analysis.

### Table 4: Mixed and Random Effects Models of Relationship of ASD Rate to Substance and Cannabinoid Exposure.

| Parameter | 1995-2011 |  |  |
|-----------|-----------|---|---|
| **Parameter** | **Value** | **Std.Error** | **df** | **t-value** | **p** | **AIC** | **BIC** | **LogLik** |
| Alcohol | -364 | 40 | 592 | -9 | 0 | -5 | 75 | 20 |
| CBN | -11 | 3 | 592 | -4.4 | 0 |  |
| Time:Alcohol | 0 | 0 | 592 | 9.1 | 0 |  |
| THC:CBD:Alcohol | -1E+05 | 22471 | 592 | -4.6 | 0 |  |
| Time:THC:CBD:Alcohol | 51 | 11 | 592 | 4.6 | 0 |  |
| Cigarettes:THC:CBD:Alcohol | 204251 | 49651 | 592 | 4.1 | 0 |  |
| Time:Cigarettes:THC:CBD:Alcohol | -102 | 25 | 592 | 4.1 | 0 |  |
| THC | -1770 | 435 | 592 | -4.1 | 1E-04 |  |
| Time:THC | 1 | 0 | 592 | 4.1 | 1E-04 |  |
| Time:CBD | 0 | 0 | 592 | 4 | 1E-04 |  |
| Time:THC:Alcohol | -2 | 0 | 592 | 3.8 | 1E-04 |  |
| THC:Alcohol | 3114 | 819 | 592 | 3.8 | 2E-04 |  |
| Cigarettes:CBD:Alcohol | -527 | 157 | 592 | 3.4 | 8E-04 |  |
| Time:THC:CBD | -13 | 5 | 592 | 2.4 | 0.018 |  |
| THC:CBD | 25439 | 10781 | 592 | 2.4 | 0.019 |  |

THC: Δ9-Tetrahydrocannabinol; CBD: Cannabidiol; CBN: Cannabinol
These findings have far reaching significance. Data demonstrate clear evidence of association between alcohol, tobacco, Δ9-tetrahydrocannabinol and cannabidiol with ASD incidence. However the present study does not occur in a vacuum, but in the context of a wealth of mechanistic studies suggesting pathways by which many cannabinoids have been shown to interfere with brain growth and maturation and fundamental neuronal physiology. This potent combination of high level epidemiological evidence and a plethora of mechanistic pathways raises a potentially causal relationship as a major issue.

The cause of ASD is not understood. Heightened startle reflex, inability to concentrate, impaired IQ and difficulty of visual processing well described in the PCE neuro-behavioural toxicology literature all bear close resemblance to various autistic features [8-11,73]. Abnormalities of cortical structure, white matter connections, and subcortical nuclei have been reported in ASD [74,75]. Similar changes have been seen after cannabis exposure [76,77] and indeed long term deficits of cortical and executive functioning have been reported in all three longitudinal studies of prenatally exposed children performed in Pittsburgh USA, Netherlands and Ottawa [8-11].

It is interesting to consider that the congenital cannabis exposure literature describes a range of defects from smaller heads, to microcephaly to anencephaly including immediate postnatal and intraterine death [8,12,78,79]. This implies a spectrum of post-PCE neurological disorders from mild to moderate to severe neurotaterology.

It should also be observed that the present findings could arise either from a generalized effect on a whole population, or from a high signal effect from tiny communities. Evidence of spatial clustering of autism in parts of Utah and California suggest that this latter effect may be of public health importance [80-82]. Such clustering is consistent with local cannabis-based subcultures and this has indeed been documented in northern California [13].

It is not our view that cannabinoids are the only cause of ASD, as we feel that cannabinoids are but one cause amongst many. However since it seems clear that cannabinoids are likely to be an important cause of ASD, and since cannabinoid use has been shown to be increasing significantly across USA in recent years including by pregnant women [83,84] it would appear that at the very least the “cannabinoid-autism link” identified in this work is a potential major driver of the rise in autism rates across the country. The data which are available do not allow us to ascertain if ASD itself is being reproduced, or if the disorder is merely being phenocopied. Given however that ASD itself represents a spectrum of disorders and is almost certainly of complex origin, this distinction would appear to be largely academic.

It is also known that cannabis can be excreted in breast milk for as long as six days after consumption [85,86]. Moreover as many as 85% of lactation consultants recently surveyed suggested that breast feeding continue in the cannabis dependent mother [87].

Our demonstration that autism rates relate closely and robustly to population exposures to cannabidiol is interesting and provocative for several reasons. In the comprehensive final model of all of the drugs by linear regression shown in Table 3 cannabidiol featured in nine terms compared to THC’s six terms, and when this exercise was repeated with a comprehensive mixed model in Table 4 cannabidiol featured in eight terms compared to THC’s four terms. Cannabidiol is widely available across USA where it is generally regarded as non-toxic and harmless due to the fact that it is not psychoactive like THC and indeed FDA is understood to be presently considering relaxing regulations in relation to it [86]. Our analysis was complicated by the generally falling concentration of cannabidiol in Federal seizures as US cannabis has been widely bred to maximize the THC content and minimize the cannabidiol content [88].

However cannabidiol is known to be both directly genotoxic [14,89-91] and to be toxic to mitochondria whose energy and normal metabolism is required for normal genome maintenance [38,39,92,93]. Proper expression of the protein complexes of the mitochondria is known to require coordinated transcription of the nuclear and genomic genomes. This is orchestrated by metabolic shuttles between the mitochondria and nucleus of key metabolites such as NAD+ (nicotinamide adenine dinucleotide cation), the malate-glucose-3-phosphate shuttle and acetyl-coenzyme A (which is the major source of acetyl groups for histone acetylation which activates gene transcription by opening the chromatin structure and making DNA accessible to the transcription machinery) together with various RNA species in addition to supplies of ATP itself [40]. ATP is required for the many energy-dependent reactions involved in DNA maintenance, transcription and nucleosomal positioning. Disruption of this delicate mitonuclear balance or the induction of the mitochondrial stress response changes the availability of metabolic substrates to the nucleus which are available to the epigenetic machinery and also changes the epigenetic state of the nuclear and mitochondrial genomes [40]. Hence the present implication of cannabidiol in ASD incidence at the epidemiological-ecological level merits further careful investigation. Given the ready and increasing availability of cannabidiol across USA, if confirmed by further studies these results may carry far reaching implications.

Whilst our study did not explicitly or by design investigate causal processes it is nevertheless of considerable interest to closely measure our findings against the suggested metrics of causality outlined classically by Bradford Hill in 1965 [66]. The nine criteria linked with causation cited by Hill were strength of association, consistency and reproducibility, specificity, temporality, biological gradient, plausibility, coherence, experiment and analogy.

Amongst these criteria, strength of association and biological gradient are clearly established by the high beta-coefficients for many of the regression equations and their vanishingly small p-values (from p<0.0001 for many cannabinoids Tables 1-4). Consistency and reproducibility is demonstrated by the persistence of these effects across the generality of US states. Specificity is shown as comparable effects were not seen for alcohol, opioids, cocaine or tobacco, some of which are known to impact brain development. Temporality is shown by the concordance of the changes in ASD over time across US states. Plausibility and coherence are demonstrated by the existence of multiple mechanistic pathways between cannabinoid exposure and abnormalities of brain development as summarized in the introduction and discussion sections of the present paper. Analogly is established by comparison with other drugs where other agents, such as SSRI antidepressants, drugs active on folic acid metabolism and cytotoxic are known to affect brain development [3-5].

Whilst this study is obviously not an experimental study, and indeed it would not be ethical to conduct such a study on human
populations, in some respects the natural variation across the various US states implies that the study is to some extent quasi-experimental in nature. The demonstration that rising cannabis use was linked with increasing rates of ASD in 50 of 51 states (Figure 5) was particularly compelling. It is important to note here that cannabis use appears to be rising across the USA irrespective of the legal status of cannabis in the various jurisdictions. That cannabis use is rising in nearly all states aligns closely with rising autism rates in nearly states. A detailed consideration of the interaction between the legal status of cannabis and the rate of autism was recently published which found an increased rate of ASD associated with more liberal paradigms of cannabis use including medical cannabis and frank cannabis legalization [23]. Thus whilst this study is not experimental per se, its quasi-experimental nature is consistent with a cannabinoid-autism link.

This brief review demonstrates that the present study in fact meets causal criteria for an association between cannabis and ASD on eight of the nine Hill criteria, whilst its quasi-experimental nature is consistent with requirements relating to experimental verification albeit whilst not being explicitly experimental in design. Findings raise special concerns in relation to introduction of cannabidiol, cannabolin and many other cannabinoids into the US food chain as is understood to be in process following the US Farm Act [86,94]. Indeed in this regard the recent experience near Ain in France near the Swiss border is relevant. Press reports disclose a 58-fold elevation of upper limb micromelia locally [95,96] along with a flourishing cannabis industry [97,98]. Micromelia was seen also in cattle—suggesting a food chain effect—but not in nearby Switzerland where cannabis had previously been banned. An epidemiological association of PCE with micromelia has been described [12]. The French investigation into this outbreak has since been re-opened.

Strengths of the present study include its relatively long duration, its national level datasets, and access to what are likely the best state-based figures of population drug use and ASD available internationally. Limitations relate to its ecological and epidemiological design and include its lack of access to individual level data and the approximations involved in approximating state level cannabinoid exposure. Both these issues can be corrected by a large case-controlled study with an objective measurement of drug exposure such as hair analysis [99].

CONCLUSION

This study confirms an association at the epidemiological-ecological level between ASD with cannabinoids Δ9-tetrahydrocannabinol and cannabidiol, and to a lesser extent tobacco and alcohol use. Since tobacco and alcohol use are declining US nation-wide [13] this implicates both psychoactive and non-psychoactive cannabinoids in the quadratically rising ASD epidemic across 49 US jurisdictions, an association which is robust to multivariate adjustment for other drug use. The relationship between cannabidiol and ASD lags by several years. Particular concerns apply to contamination of the national food supply with cannabinoids and their asymptotic neurotoxicity and genotoxicity. In the context of multiple previously established mechanistic pathways these association-level findings are consistent with a casual pathway and position cannabis as a major suspect driving the present epidemic. We advocate a large case-controlled study be undertaken including objective measures of drug exposure to investigate dose-response and putatively causal effects.

FUNDING SOURCE

No external funding for this study.

FINANCIAL DISCLOSURE

The authors have indicated they have no financial relationships to this article to disclose.

CONFLICT OF INTEREST

The authors have indicated they have no potential conflicts of interest to disclose.

ACKNOWLEDGEMENT

Dr Reece designed the study, performed the statistical analysis and wrote the first draft.

Prof Hulse reviewed the manuscript for important intellectual content and revised the draft. He also provided administrative, research support and assisted with statistical advice and oversight. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

REFERENCES

1. Developmental Disabilities Monitoring Network Surveillance Year Principal I, Centers for Disease C, Prevention. Prevalence of autism spectrum disorder among children aged 8 years · autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014;63(2):1-21.
2. Reyher J, Crowder L, HB18-1223: Declare Autism Epidemic in Colorado. In. Edited by Assembly CHoRotCG, vol. 1. Denver, Colorado, USA. Colorado 2018.
3. Durkin MS, Maenner MJ, Newschaffer CJ, Lee LC, Cunniff CM, Daniels JL, et al. Advanced parental age and the risk of autism spectrum disorder. Am J Epidemiol. 2008;168(11):1268-1276.
4. Osokine I, Erlebacher A. Inflammation and Autism: From Maternal Gut to Fetal Brain. Trends Mol Med. 2017;23(12):1070-1071.
5. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Advanced parental age and autism risk in children: a systematic review and meta-analysis. Acta Psychiatr Scandinavica. 2017;135(1):29-41.
6. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080.
7. Foldy C, Malenka RC, Sudhof TC. Autism-associated neurulin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):498-509.
8. Brents L. Correlates and consequences of Prenatal Cannabis Exposure (PCE): Identifying and Characterizing Vulnerable Maternal Populations and Determining Outcomes in Exposed Offspring In: Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis and Treatment. Volume I, edn. Edited by Preedy V.R. London: Academic Press. 2017:160-170.
9. Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. Neurotoxicol Teratol. 2006;28(2):286-295.
10. Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl). 2010;210(3):429-438.
11. Smith AM, Mioduszewski O, Hatchard T, Byron-Alhassan A, Fall C.
Fried PA. Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. Neurotoxicol Teratol. 2016;58:53-59.

12. Forrester MB, Mertz RD. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002. J Toxicol Environ Health. 2007;70(1):7-18.

13. National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. (2005).

14. Russo C, Ferk F, Misik M, Ropek N, Nersesyan A, Mejri D. Low doses of widely consumed cannabinoids (cannabidiol and cannabivarindin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;93(1):171-188.

15. Singh N, Hroudova J, Fisar Z. Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J Mol Neurosci. 2015;56(4):926-931.

16. Fisar Z, Singh N, Hroudova J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicology Letters. 2014;231(1):62-71.

17. Sarafian TA, Habib N, Oldham M, Seeram N, Lee RP, Lin L. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. American Journal of Physiology. 2006; 290(6):L1202-1209.

18. Sarafian TA, Koyoumjian S, Khoshaghilideh F, Tashkin DP, Roth MD. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. American Journal of Physiology. 2003;284(2):L298-306.

19. Noonan MA, Eisch AJ. Regulation of Adult Neurogenesis by Cannabinoids. Chemistry Today. 2006; 24(5):84-88.

20. Reece AS, Norman A, Hulse GK. Cannabis Exposure as an Interactive Cardiovascular Risk Factor and Accelerant of Organising Age – A Longitudinal Study. BJM - Open. 2016;6(11):e011891-e011900.

21. Reece AS, Hulse GK. Chromothripsis and epigenomics complete the puzzle in cannabis-exposed animals. Cell. 2018;174(3):590-606 e521.

22. Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure and long-term changes in motor and sensory function. Clin Pediatr, Vol. 4 Iss. 2 No: 155

23. Noonan MA, Eisch AJ, Reguero L, Puente N, Lutz B, Chaouloff F, et al. Evolution of Cortical Neurogenesis in Amniotes Controlled by Robo Signaling. Cell. 2015;33(7):668-685.

24. Alpar A, Tortoriello G, Calvigioni D, Niphakis MJ, Milenkovic I, Bakker J, et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. Nat Commun. 2014;5:4421.

25. Cardenas A, Villalba A, de Juan Romero C, Pico E, Kyrousi C, Tzika AC, et al. Evolution of Cortical Neurogenesis in Amniotes Controlled by Robo Signaling Levels. Cell. 2018;174(3):590-606 e521.

26. Kim D, Lim S, Park M, Choi J, Kim J, Han H, et al. Ubiquitination-dependent CAR1 degradation facilitates Notch1-mediated podocyte apoptosis in diabetic nephropathy. Cell Signalling. 2014; 26(9):1774-1782.

27. Tanveer R, Gowran A, Noonan J, Keating SE, Bowie AG, Campbell VA. The endocannabinoid, anandamide, augments Notch-1 signalling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats. J Biol Chem. 2012; 287(41):34709-34721.

28. Carlsson BM. Human Embryology and Developmental Biology, vol. 1. Philadelphia: Elsevier. 2014.

29. Androustelli-Theotokis A, Leker RR, Soldner F, Hoepfner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442(7104):823-826.

30. Siummann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature. 2007;445(7129):781-784.

31. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coulitas L, Lindblom F, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445(7129):776-780.

32. Anavi-Goffer S, Mulder J. The polarised nature of the endocannabinoid system in CNS development. Chembiochem. 2009;10(10):1591-1598.

33. Argaw A, Duff G, Zabouri N, Ceycre B, Chaine N, Cherif H, et al. Concerted action of CB1 cannabinoid receptor and deleted in colorectal cancer in axon guidance. J Neurosci. 2011;31(4):1489-1499.

34. Anderson GR, Aoto J, Tabuchi K, Foldy C, Covey J, Yee AX, et al. beta-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling. Cell. 2015;162(3):593-606.

35. Cutando L, Maldonado R, Ozaita A. Microglial Activation and Cannabis Exposure. In: Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis and Treatment. Volume 1, edn. Edited by V. P. New York: Academic Press. 2017;401-412.

36. Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, et al. Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SGC10/statmin-2 degradation pathway. EMBO J. 2014;33(7):668-685.

37. Martel G, Uchida S, Hevi C, Chevere-Torres I, Fuentes I, Park YJ, et al. Genetic Demonstration of a Role for Statomin in Adult Hippocampal Neurogenesis, Spino genesis, and NMDA Receptor-Dependent Memory. J Neurosci. 2016;36(4):1185-1202.

38. Harkany T, Horvath TL. (S)Rot on Mitochondria: Cannabinoids Disrupt Cellular Respiration to Limit Neuronal Activity. Cell Metab. 2017;25(1):8-10.

39. Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, Busquets-Garcia A, et al. A cannabinoid link between mitochondria and memory. Nature. 2016;539(7630):555-559.

40. Canto C, Menzies KJ, Anwerx J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22(1):31-53.

41. Wolff V, Schlagowski AI, Rouyer O, Charles AL, Singh F, Auger C, et al. Tetrahydrocannabinol induces brain mitochondrial respiratory chain dysfunction and increases oxidative stress: a potential mechanism involved in cannabis-related stroke. Biomed Res Int. 2015;2015:323706.

42. Laprairie RB, Bagher AM, Kelly ME, Dupre DJ, Denovan-Wright EM. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem. 2014;289(36):24845-24862.

43. Hebert-Chatelain E, Reguero L, Puente N, Lutz B, Chaouloff F, Rossignol R, et al. Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor. Mol Metab. 2014;3(4):495-504.

44. Chuichiu V. Endocannabinoids and Immunity. Cannabis Cannabinoid Res. 2016;1(1):59-66.

45. Zembrun EE, Sido JM, Nagarkatti PS, Nagarkatti M. Epigenetic Regulation of Immunological Alterations Following Prenatal Exposure to Marijuana Cannabinoids and its Long Term Consequences in Offspring. J Neuroimmune Pharmacol. 2015;10(2):245-254.

46. Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron. 2009;64(1):93-109.
47. Carpentier PA, Palmer TD. Immune influence on adult neural stem cell regulation and function. Neuron. 2009;64(1):79-92.

48. Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009;64(1):61-78.

49. Barber PA, Pridmore HM, Krishnamurthy V, Roberts S, Spriggs DA, Carter KN, et al. Cannabis, ischemic stroke, and transient ischemic attack: a case-control study. Stroke; A Journal of Cerebral Circulation. 2013;44(8):2327-2329.

50. Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151-166.

51. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014; 371(9):879.

52. Zong Y, Zhou X, Cheng J, Yu J, Wu J, Jiang C. Cannabinoids Regulate the Diameter of Pericyte-Containing Retinal Capillaries in Rats. Cell Physiol Biochem. 2017;43(5):2088-2101.

53. Schuel M, Chang MC, Burkman LJ, Picone RP, Makriyannis A, Zimmerman A M et al. Cannabinoid Receptors in Sperm. In: Marijuana in Medicine. Volume 1, 1 edn. Edited by Nahas GG, Sutin K.M., Harvey D.J, Agurell S. Totowa, New Jersey. Humana Press. 1999:335-346.

54. Zimmerman AM, Zimmerman S, Raj AY. Effects of Cannabinoids on Spermagotaxis in Mice. In: Marijuana and Medicine. Volume 1, 1 edn. Edited by Nahas GG, Sutin K.M., Harvey D.J, Agurell S. Totowa, New York. Humana Press. 1999:347-358.

55. Hembree WC, Nahas GG, Zeidenberg P, Huang HF. Changes in human spermatozoa associated with high dose marihuana smoking. Adv Biosci. 1978;22-23:429-439.

56. Huang HFS, Nahas GG, Hembree WC. Effects of marijuana inhalation on spermagotaxis of the rat. In: Marijuana and medicine. edn. Edited by Nahas G.C. SKM, Harvey D.J., Agurell S. Totowa, New Jersey. Humana Press. 1999:359-366.

57. Morishima A. Effects of cannabis and natural cannabinoids on chromosomes and ova. NIDA Res Monogr. 1984;44:25-45.

58. Selenkow O, Tobias AJ, Jackson JS, Sullivan R, Ma D, Sullivan JP, et al. Maternal alcohol exposure during mid-pregnancy dilates fetal cerebral arteries via endocannabinoid receptors. Alcohol (Fayetteville, NY. 2017;61:51-61.

59. Sheriff MA, Cortes-Briones JA, Ranganathan M, Skosnik PD. Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis. Eur J Neurosci. 2018;48(8):2890-2902.

60. Dinieri JA, Wang X, Szutorisz H, Smapo SM, Kaur J, Casaccia P, et al. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry. 2011;70(8):763-769.

61. Murphy SK, Ichon-Ramos N, Visco Z, Huang Z, Grenier C, Schrott R, et al. Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics. 2018;13(12):1208-1221.

62. Szutorisz H, DiNieri JA, Smapo E, Egervari G, Michaelides M, Carter JM, et al. Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology. 2014;39(6):1315-1323.

63. Yang X, Hegde VL, Rao B, Zhang J, Nagarkati PS, Nagarkarti M. Histone modifications are associated with Delta9-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses. J Biol Chem. 2014;289(27):18707-18718.

64. Waye MMY, Cheng HY. Genetics and epigenetics of autism: A Review. Psychiatry Clin Neurosci. 2018;72(4):228-244.

65. Siu MT, Welsberg R. Epigenetics of Autism Spectrum Disorder. Adv Exp Med Biol. 2017;978:63-90.

66. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965;58:295-302.

67. Nevison C, Blaxill M, Zahorodny W. California Autism Prevalence Trends from 1991 to 2014 and Comparison to National ASD Data from IDEA and ADDM. J Autism Dev Disord. 2018;48(12):4103-4117.

68. EI-Sohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol Psychiatry. 2016;79(7):613-619.

69. EI-Sohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of deltaTHC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Sci. 2000; 45(1):24-30.

70. Adam JM. Facing Addiction in America: The Surgeon General’s Report on Alcoh, Drugs and Health. In. Edited by Office of the Surgeon General UDoHaHS, vol. 1. Washington DC: Health and Human Services. 2016;1-82.

71. Murphy VH. Ending the Opioid Epidemic - A Call to Action. N Engl J Med. 2016;375(25):2413-2415.

72. Substance Abuse and Pregnancy. Women’s Health Care Physicians.

73. Vargish GA, Pelkey KA, Yuan X, Chitrajalu R, Collins D, Fang C, et al. Persistent inhibitory circuit defects and disrupted social behaviour following in utero exogenous cannabinoid exposure. Mol Psychiatry. 2017;22(1):5667.

74. Arnold Anteraper S, Guell X, D’Mello A, Joshi N, Whitfield-Gabrieli S, Joshi G. Disrupted Cerebrocerebellar Intrinsic Functional Connectivity in Young Adults with High-Functioning Autism Spectrum Disorder: A Data-Driven, Whole-Brain, High-Temporal Resolution Functional Magnetic Resonance Imaging Study. Brain Connect. 2018;8(1):48-59.

75. Yang Q, Huang P, Li C, Fang P, Zhao N, Nan J, et al. Mapping alterations of gray matter volume and white matter integrity in children with autism spectrum disorder: evidence from fMRI findings. Neuroreport. 2018;29(14):1188-1192.

76. Zalesky A, Solowij N, Yucel M, Lubman DI, Takagi M, Harding IH, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain. 2012;135(Pt 7):2245-2255.

77. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban BM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316(5828):1212-1216.

78. Van Gelder MMHJ, Donders ART, Devine O, Roeleveld N, Reehuis J. Using bayesian models to assess the effects of under-reporting of cannabis use on the association with birth defects, national birth defects prevention study, 1997-2005. Paediatr Perinat Epidemiol. 2014;28(5):424-433.

79. Van Gelder MMHJ, Reehuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology. 2009;20(1):60-66.

80. Bakian AV, Bildner DA, Coon H, McMahon WM. Spatial relative risk patterns of autism spectrum disorders in Utah. J Autism Dev Disord. 2018;45(4):988-1000.

81. Mazumdar S, King M, Liu KY, Zerubavel N, Bearman P. The spatial structure of autism in California, 1993-2001. Health Place. 2010;16(3):539-546.

82. Van Meter KC, Christiansen LE, Delwiche LD, Azari R, Carpenter TE, Hertz-Picciotto I. Geographic distribution of autism in California: a retrospective birth cohort analysis. Autism Res. 2010;3(1):19-29.

83. Agrawal A, Rogers CE, Lessov-Schlaggar CN, Carter EB, Lenze SN, Grucza RA, Alcohol, Cigarette, and Cannabis Use Between 2002 and 2016 in Pregnant Women From a Nationally Representative Sample. JAMA Pediatr. 2018.
84. Agrawal A, Grucza RA, Rogers CE. Public Health Implications of Rising Marijuana Use in Pregnancy in an Age of Increasing Legalization—Reply. JAMA Pediatr. 2019.

85. Bertrand KA, Hanan NJ, Honerkamp-Smith G, Best BM, Chambers CD. Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk. Pediatrics. 2018;142(3):e20181076.

86. FDA weighs legalizing interstate sales of cannabis-based CBD in food and drinks. Health and Science. 2018.

87. Bergeria CL, Heil SH. Surveying Lactation Professionals Regarding Marijuana Use and Breastfeeding. Breastfeed Med. 2015;10(7):377-380.

88. White CM. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. 2019.

89. Karmaus PW, Wagner JG, Harkema JR, Kaminski NE, Kaplan BL. Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. J Immunotoxicol. 2013;10(3):321-328.

90. Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE. Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium. Genes Cancer. 2012;3(7-8):512-520.

91. Pucci M, Rapino C, Di Francesco A, Dainese E, D’Addario C, Maccarrone M. Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol. 2013;170(3):581-591.

92. Chiu P, Karler R, Craven C, Olsen DM, Turkanis SA. The influence of delta-9-tetrahydrocannabinol, cannabidiol and cannabidiol on tissue oxygen consumption. Res Commun Chem Pathol Pharmacol. 1975;12(2):267-286.

93. Koch M, Varela L, Kim JG, Kim JD, Hernandez-Nuno F, Simonds SE, et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature. 2015;519(7541):45-50.

94. Cannabis food, drinks to be 2019’s hottest dining trend, top chefs say. Cannabis food, drinks to be 2019's hottest dining trend, top chefs say. USA Today. 2019.

95. Willsher K. Baby arm defects prompt nationwide investigation in France. In: Guardian. London: The Guardian. 2018.

96. Agence France-Presse in Paris: France to investigate cause of upper limb defects in babies. In: The Guardian. London: The Guardian. 2018.

97. Le Figaro with AFP: Ain: seizure of 135kg of cannabis. In: Le Figaro: Paris France. 2018.

98. Connexion Journalist: Mayor wants to grow and sell cannabis in French fields. In: France. 2018.

99. David AL, Holloway A, Thomasson L, Syngelaki A, Nicolaides K, Patel RR, et al. A case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysis. PLoS One. 2014;9(10):e111038.